Anti-NGF antibodies and methods using same
The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
1. An isolated antibody comprising:
1) a heavy chain variable region comprising:
(a) the CDR1 region shown in SEQ ID NO:3,
(b) the CDR2 region shown in SEQ ID NO:4, and
(c) the CDR3 region shown in SEQ ID NO:5; and
2) a light chain variable region comprising:
(a) the CDR1 region shown in SEQ ID NO:6;
(b) the CDR2 region shown in SEQ ID NO:7, and
(c) the CDR3 region shown in SEQ ID NO:8;
wherein the antibody binds NGF.
2. The antibody of claim 1 , wherein the heavy chain variable region consists of the sequence shown in SEQ ID NO:1.
3. The antibody of claim 1 , wherein the light chain variable region consists of the sequence shown in SEQ ID NO:2.
4. The antibody of claim 2 , wherein the light chain variable region consists of the sequence shown in SEQ ID NO:2.
5. The antibody of claim 1 , wherein the heavy chain consists of the amino acid sequence shown in SEQ ID NO:16.
6. The antibody of claim 1 , wherein the light chain consists of the amino acid sequence shown in SEQ ID NO:17.
7. The antibody of claim 5 , wherein the light chain consists of the amino acid sequence shown in SEQ ID NO:17.
8. The antibody of claim 1 , wherein the antibody is humanized.
9. The antibody of claim 1 , wherein the antibody is affinity matured.
10. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.
11. A pharmaceutical composition comprising (a) the antibody of claim 1 , and (b) a pharmaceutically acceptable excipient.
12. A kit comprising the antibody of claim 1 .